Advancing novel, small molecule treatments targeting epigenetic mechanisms in tumor and immune cells for the benefit of patients

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel small molecule therapies based on its pioneering research in cancer epigenetics. With a decade of experience in the field, the company has an unparalleled understanding of how epigenetic regulators modulate gene expression in cancer cells and in the tumor and immune microenvironment. Constellation is translating these insights to advance the company’s two lead clinical programs, CPI-1205 and CPI-0610, and in novel targets for which cancer epigenetics may help overcome resistance mechanisms to currently available treatment options.

Year Invested: 2008
Location: Cambridge, Mass.

Recent News

February 9, 2018
Constellation Pharmaceuticals Announces Upcoming Presentations of Lead EZH2 and BET Clinical Programs

January 16, 2018
Constellation Pharmaceuticals Announces Initiation of Phase 1b/2 Study of CPI-1205

January 4, 2018
Constellation Pharmaceuticals to Present at 36th Annual JP Morgan Healthcare Conference

Read More News

Associated Team Members

Robert Tepper, M.D.

Neil Exter

Mark A. Goldsmith, M.D., Ph.D.
Venture Partner

Craig Muir
Partner/Chief Technology Officer

Mark Levin

Keith Dionne, Ph.D.